The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the U.S. health regulator approved the drug, giving patients new hope of interrupting virus transmission.
The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care.
"While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus, WHO Director-General.
The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist.
These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents.
WHO has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly procedures.
Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.
The recommendation, issued at the International AIDS Conference in Kigali, Rwanda, comes nearly a month after the U.S. health regulator approved the drug, giving patients new hope of interrupting virus transmission.
The twice-yearly injectable offers a long-acting alternative to daily oral pills and other shorter-acting options, reshaping the response to the disease especially among those who face challenges with daily adherence, stigma, or access to health care.
"While an HIV vaccine remains elusive, lenacapavir is the next best thing," said Tedros Adhanom Ghebreyesus, WHO Director-General.
The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 as funding challenges, stigma around the disease persist.
These infections disproportionately impact populations such as sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents.
WHO has also recommended a public health approach to HIV testing using HIV rapid tests that would remove a major access barrier by eliminating complex and costly procedures.
Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year.
You may also like
David Kaff dead: This Is Spinal Tap icon dies aged 79 as friends pay tribute
This Morning presenter Dermot O'Leary 'lands major new Channel 5 gameshow'
Matt Damon, Tom Holland, Zendaya spotted filming for Christopher Nolan's 'The Odyssey' in Scotland
When is the next Nintendo Direct? One insider may have the answer
Love Island stars announce shock engagement one year on from meeting on ITV2 show
